Group 1 - The company has signed a licensing agreement for the RAY1225 injection project with Qilu Pharmaceutical, which includes a $20 million upfront payment [2] - The company has confirmed receipt of the upfront payment, which will effectively supplement its cash flow and optimize its cash flow structure [2] - This licensing agreement is expected to have a positive impact on the company's future operational development [2]